The results from numerous studies analysing the immunosuppressive and pro-angiogenic influence of Gal1 on tumour growth, proliferation, and apoptosis have evidently demonstrated the stark possibilities that Gal1 presents as a cancer therapeutic target. This evidence concerns the gene LGALS1 and cancer.